Granocyte

Granocyte is a pharmaceutical product containing the active ingredient lenograstim, supplied in an injectable form for intravenous or subcutaneous administration. It is marketed in the European Union and is used as a recombinant granulocyte colony‑stimulating factor to support neutrophil production in patients with certain hematologic conditions. The preparation is typically provided as a sterile solution without preservatives, intended for use under the supervision of a qualified healthcare professional.

Granocyte (lenograstim) is indicated for clinical situations where stimulation of white blood cell production is required.

- To reduce the duration of neutropenia in patients receiving myelosuppressive chemotherapy. - To accelerate neutrophil recovery after autologous or allogeneic stem cell transplantation. - To support hematopoietic recovery in patients with severe chronic neutropenia. - To mobilize peripheral blood stem cells for collection prior to transplantation.

The safety profile of lenograstim includes a range of observed adverse events, which are generally categorized by frequency and severity.

Common: - Bone pain, often in the lower back or limbs. - Mild fever or flu‑like symptoms. - Injection site reactions such as redness or swelling.

Serious: - Splenic enlargement or rupture. - Severe allergic reactions, including anaphylaxis. - Thromboembolic events such as deep vein thrombosis.

When prescribing or administering Granocyte, healthcare professionals should consider several precautionary measures to minimize risk.

- Assess baseline neutrophil count and overall bone marrow function before initiating therapy. - Monitor for signs of splenomegaly during treatment, especially in patients with pre‑existing splenic conditions. - Use the lowest effective dose and limit duration to reduce the likelihood of bone pain and other adverse effects. - Avoid concurrent use with other myeloid growth factors unless specifically indicated. - Evaluate for hypersensitivity history; discontinue if an allergic reaction occurs. - Exercise caution in patients with a history of thromboembolic disease.

Lenograstim may interact with other medications or clinical conditions, requiring careful assessment to avoid adverse outcomes.

Avoid: - Concurrent administration with other granulocyte colony‑stimulating factors (e.g., filgrastim) unless directed. - Use with investigational agents that suppress bone marrow function without medical supervision.

Use with caution: - Anticoagulants or antiplatelet agents, due to potential increased risk of thrombosis. - Corticosteroids, which may mask signs of infection. - Chemotherapy regimens, requiring timing adjustments to align with neutrophil recovery.